Lyra Therapeutics, Inc. Quarterly Debt-to-equity in % from Q3 2020 to Q4 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Lyra Therapeutics, Inc. quarterly Debt-to-equity history and growth rate from Q3 2020 to Q4 2024.
  • Lyra Therapeutics, Inc. Debt-to-equity for the quarter ending December 31, 2024 was 171 %, a 301% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q4 2024 171 +128 +301% Dec 31, 2024
Q3 2024 109 +72.8 +199% Sep 30, 2024
Q2 2024 77 +44.4 +136% Jun 30, 2024
Q1 2024 51.7 +20.8 +67.1% Mar 31, 2024
Q4 2023 42.7 +8.63 +25.3% Dec 31, 2023
Q3 2023 36.5 -0.3 -0.82% Sep 30, 2023
Q2 2023 32.6 -9.6 -22.8% Jun 30, 2023
Q1 2023 30.9 -20.9 -40.4% Mar 31, 2023
Q4 2022 34.1 +2.42 +7.65% Dec 31, 2022
Q3 2022 36.8 +16.1 +77.8% Sep 30, 2022
Q2 2022 42.2 +29 +220% Jun 30, 2022
Q1 2022 51.8 +44 +568% Mar 31, 2022
Q4 2021 31.6 +9.1 +40.4% Dec 31, 2021
Q3 2021 20.7 +53.9 Sep 30, 2021
Q2 2021 13.2 Jun 30, 2021
Q1 2021 7.75 Mar 31, 2021
Q4 2020 22.5 Dec 31, 2020
Q3 2020 -33.1 Sep 30, 2020
* An asterisk sign (*) next to the value indicates that the value is likely invalid.